Abstract | BACKGROUND: METHODS: To evaluate the growth inhibitory effects of CUR, DMC and BDMC on osteosarcoma (HOS and U2OS), breast (MDA-MB-231), and melanoma (A2058) cancer cells, we employed the MTT assay, annexin V-FITC /7-AAD staining, and clonogenic assay. RESULTS: CUR,DMC, and BDMC all decreased the viability of HOS, U2OS, MDA-MB-231, and A2058 cancer cells. Additionally, CUR,DMC, and BDMC induced the apoptosis of HOS cells through activation of Smad 2/3 or repression of Akt signaling pathway. Furthermore, the combination of CUR,DMC, and BDMC synergistically reduced cell viability, colony formation and increased apoptosis than either two or a single agent in HOS cells. CONCLUSIONS: The combination of these three compounds could be used as a novel target for the treatment of osteosarcoma.
|
Authors | Cheng Huang, Hsu-Feng Lu, Yu-Hsuan Chen, Jui-Chieh Chen, Wen-Hsiang Chou, Hsiu-Chen Huang |
Journal | BMC complementary medicine and therapies
(BMC Complement Med Ther)
Vol. 20
Issue 1
Pg. 68
(Mar 03 2020)
ISSN: 2662-7671 [Electronic] England |
PMID | 32126993
(Publication Type: Journal Article)
|
Chemical References |
- Diarylheptanoids
- Smad Proteins
- bisdemethoxycurcumin
- Proto-Oncogene Proteins c-akt
- Caspases
- Curcumin
- demethoxycurcumin
|
Topics |
- Apoptosis
(drug effects)
- Caspases
(metabolism)
- Cell Line, Tumor
- Curcumin
(chemistry, pharmacology)
- Diarylheptanoids
(chemistry, pharmacology)
- Drug Therapy, Combination
- Humans
- Molecular Structure
- Proto-Oncogene Proteins c-akt
(metabolism)
- Signal Transduction
- Smad Proteins
(metabolism)
|